Renal Biomarker Market: Rising Prevalence of Renal Diseases Fuelling Demand for Renal Biomarkers: Global Industry Analysis and Opportunity Assessment, 2016-2026
- REP-GB-1731
- 2016-11-22
- Category: Healthcare, Pharmaceuticals and Medical devices
- 190 Pages
- Format:
Kidney diseases are one of the leading causes of death worldwide. The incidence of chronic kidney diseases is rapidly rising especially in the elderly population due to increase in life expectancy of general population and improvements in medical management services. However, diabetes and hypertension remain the leading cause of renal diseases. Biomarkers are measurable indicators reflecting physiological and pharmacological progression of disease state. Recent advances in molecular biology have resulted in the development of novel biomarkers for the renal function. Extensive R&D by biomarker manufacturers has led to identification of novel renal biomarkers to deliver better diagnostic accuracy and improve patient outcomes.
Market forecast
Revenue from the global renal biomarker market is projected to register a CAGR of 7.0% during the forecast period (2016 – 2026) and reach a market valuation of US$ 1,770.3 Mn by the end of 2026.
Rising prevalence of renal diseases primary driver boosting market growth
Growth of the global renal biomarker market is mainly driven by rising prevalence of various renal diseases coupled with an ageing population worldwide. Also, there has been an increase in the adult population with chronic kidney diseases, primarily attributed to a rising prevalence of conditions such as diabetes and high blood pressure. Other prominent growth factors include large number of clinical trials in the novel renal biomarker and drug development space and penetration of various cost-effective, reliable, and rapid technologically driven diagnostic protocols in clinical practice. However, use of unreliable imperfect gold standard for renal disease diagnosis and lack of sensitivity and specificity in current renal biomarkers are some of the factors restraining the growth of the market over the forecast period.
Current trends governing the global renal biomarker market include the possible use of renal biomarkers in personalised medicine and drug development and a growing popularity of non-invasive renal biomarkers.
Market segmentation
|
By Biomarker Type |
By Diagnostic Technique |
By End User |
By Region |
|---|---|---|---|
|
|
|
|
Functional Biomarker type segment expected to remain the dominant segment over the forecast period
The Functional Biomarker segment is anticipated to account for a market value share of 52.3% by the end of 2016 and is expected to retain its dominance throughout the forecast period. The Up-Regulated Proteins segment is estimated to account for 33.8% market share in terms of value by 2016 end.
Enzyme Linked Immunosorbent Assay diagnostic technique segment estimated to hold the highest market share throughout the forecast period
The Enzyme Linked Immunosorbent Assay segment is anticipated to register a CAGR of 8.1% over the forecast period and is expected to register high Y-o-Y growth rates from 2016 to 2026. The Particle-Enhanced Turbidimetric Immunoassay segment is estimated to be the second largest segment in terms of value, holding a market value share of 21.0% by 2016 end.
Diagnostic Labs end user segment expected to witness highest growth in terms of revenue throughout the forecast period
The Diagnostic Labs segment is estimated to account for 34.2% market share of the global renal biomarker market in revenue terms by 2016 end and is expected to register high Y-o-Y growth rates throughout the forecast period. The Outpatient Clinics segment is anticipated to register a CAGR of 7.2% during the forecast period.
North America renal biomarker market expected to register high Y-o-Y growth throughout the forecast period
The North America regional market is estimated to account for 32.2% revenue share of the global renal biomarker market by 2016 end. Western Europe is estimated to hold the second largest market share of 21.1% by 2016 end.
Leading market players are emphasising on product innovation and strategic acquisitions to increase market share
Beckman Coulter, Inc. (Danaher Corporation), Thermo Fisher Scientific Inc., Abbott Laboratories, BIOPORTO A/S, Astute Medical, Inc., and Randox Laboratories Ltd. are some of the key players operating in the global renal biomarker market. Top market companies are focussing on increasing their presence in high-growth emerging markets through structured investments in R&D and technological innovation.
Future Market Insights examines the global renal biomarker market for the period 2016–2026 in a new report titled “Renal Biomarker Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” The primary objective of the report is to offer updates and in-depth analysis of market opportunities in the global renal biomarker market. The report offers a global market forecast in terms of value for the next 10 years.
Report description
To understand and assess opportunities in this market, the report is categorically split under four sections based on market segmentation – by biomarker type, diagnostic technique, end user, and region. The report analyses the global renal biomarker market in terms of market value (US$ Mn). The report begins with an overview of various types of renal diseases and addressable biomarker followed by a market forecast for the period 2016 – 2026. We have also presented a detailed analysis of key trends and drivers from the economic and supply and demand perspectives, market restraints, and trends likely to impact the global renal biomarker market. The subsequent sections analyse the global renal biomarker market on the basis of biomarker type, diagnostic technique, end user, and region and present a comprehensive forecast in terms of value for the next 10 years. Our study further discusses the key trends across the various assessed regions and analyses the degree to which drivers are influencing the market in each region.
In the final section of the report, we have included the global renal biomarker market competitive landscape to provide report audiences with a dashboard view of key renal biomarker providers, their presence in the global renal biomarker market, and key differentiators. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the global renal biomarker market. We have further profiled the leading players on the basis of various attributes such as company overview, recent developments, growth strategies, sustainability, and financial overview to evaluate their long- and short-term strategies, key offerings, and recent developments in the global renal biomarker market.
Research methodology
We have leveraged extensive secondary research to ascertain overall market size and top industry players. To arrive at the market size, the report considers average price of renal biomarker assays across geographies. The forecast presented here assesses the total revenue of the global renal biomarker market. When developing the market forecast, the starting point involves sizing the current market, which forms the basis for forecasting how the market is anticipated to take shape in the near future. Given the characteristics of the market, we have triangulated the outcome on the basis of supply and demand side analysis. The report also takes into consideration year-on-year growth to understand the predictability of the market and to identify the right opportunities across the global renal biomarker market.
Further, the different market segments have been analysed in terms of Basis Point Share (BPS) to understand individual segments’ relative contribution to market growth. This detailed level of information is important for the identification of various key trends governing the global renal biomarker market. Another key feature of our report is the analysis of the global renal biomarker market by region, biomarker type, diagnostic technique, and end user, and its revenue forecast in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical in assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales perspective in the global renal biomarker market. Further, to understand key segments in terms of growth and performance in the global renal biomarker market, Future Market Insights has developed a market attractiveness index to help providers identify existing market opportunities across the global renal biomarker market.
Renal Biomarker Market Reports - Table of Contents
1. Executive Summary
2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy
3. Global Renal Biomarker Market Analysis Scenario
3.1. Market Size (US$ Mn) and Forecast
3.1.1. Market Size and Y-o-Y Growth
3.1.2. Absolute $ Opportunity
3.2. Market Overview
4. Market Dynamics
4.1. Macro-economic Factors
4.2. Drivers
4.2.1. Supply Side
4.2.2. Demand Side
4.3. Restraints
4.4. Opportunity
4.5. Forecast Factors – Relevance and Impact
4.6. Diseases Epidemiology
5. Global Renal Biomarker Market Analysis and Forecasts, By Biomarker Type
5.1. Introduction
5.2. Basis Point Share (BPS) Analysis By Biomarker Type
5.3. Y-o-Y Growth Projections By Biomarker Type
5.4. Market Value Forecast By Biomarker Type , 2015–2026
5.4.1. Functional Biomarker
5.4.1.1. Serum Creatinine
5.4.1.2. Serum Cystatin C
5.4.1.3. Urine Albumin
5.4.2. Up-Regulated Proteins
5.4.2.1. Neutrophil Gelatinase-Associated Lipocalin
5.4.2.2. Kidney Injury Molecule-1
5.4.2.3. Interleukin-18
5.4.3. Others
5.5. Prominent Trends
5.6. Market Attractiveness By Biomarker Type
6. Global Renal Biomarker Market Analysis and Forecasts, By Diagnostic Technique
6.1. Introduction
6.2. Basis Point Share (BPS) Analysis By Diagnostic Technique
6.3. Y-o-Y Growth Projections By Diagnostic Technique
6.4. Market Value Forecast By Diagnostic Technique , 2015–2026
6.4.1. Enzyme Linked Immunosorbent Assay (ELISA)
6.4.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)
6.4.3. Colorimetric Assay
6.4.4. Chemiluminescent Enzyme Immunoassay (CLIA)
6.4.5. Liquid Chromatography-Mass Spectrometry (LS-MS)
6.5. Prominent Trends
6.6. Market Attractiveness By Diagnostic Technique
7. Global Renal Biomarker Market Analysis and Forecasts, By End User
7.1. Introduction
7.2. Basis Point Share (BPS) Analysis By End User
7.3. Y-o-Y Growth Projections By End User
7.4. Market Value Forecast By End User , 2015–2026
7.4.1. Diagnostic Labs
7.4.2. Outpatient Clinics
7.4.3. Research Centers
7.4.4. Hospitals
7.5. Prominent Trends
7.6. Market Attractiveness By End User
8. Global Renal Biomarker Market Analysis and Forecasts, By Region
8.1. Basis Point Share (BPS) Analysis By Country
8.2. Y-o-Y Growth Projections By Country
8.3. Market Value Forecast By Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. Asia Pacific Excluding Japan (APEJ)
8.3.6. Japan
8.3.7. Middle East and Africa (MEA)
8.4. Market Attractiveness By Country/Region
9. North America Renal Biomarker Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis By Country
9.1.2. Y-o-Y Growth Projections By Country
9.1.3. Key Regulations
9.2. Market Value Forecast By Biomarker Type , 2015–2026
9.2.1. Functional Biomarker
9.2.1.1. Serum Creatinine
9.2.1.2. Serum Cystatin C
9.2.1.3. Urine Albumin
9.2.2. Up-Regulated Proteins
9.2.2.1. Neutrophil Gelatinase-Associated Lipocalin
9.2.2.2. Kidney Injury Molecule-1
9.2.2.3. Interleukin-18
9.2.3. Others
9.3. Market Value Forecast By Diagnostic Technique , 2015–2026
9.3.1. Enzyme Linked Immunosorbent Assay (ELISA)
9.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)
9.3.3. Colorimetric Assay
9.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)
9.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)
9.4. Market Value Forecast By End User , 2015–2026
9.4.1. Diagnostic Labs
9.4.2. Outpatient Clinics
9.4.3. Research Centers
9.4.4. Hospitals
9.5. Market Value Forecast By Country , 2015–2026
9.5.1. The U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Biomarker Type
9.6.2. By Diagnostic Technique
9.6.3. By End User
9.6.4. By Country
9.7. Prominent Trends
9.8. Drivers and Restraints: Impact Analysis
10. Latin America Renal Biomarker Market Analysis and Forecast
10.1.Introduction
10.1.1. Basis Point Share (BPS) Analysis By Country
10.1.2. Y-o-Y Growth Projections By Country
10.1.3. Key Regulations
10.2.Market Value Forecast By Biomarker Type , 2015–2026
10.2.1. Functional Biomarker
10.2.1.1. Serum Creatinine
10.2.1.2. Serum Cystatin C
10.2.1.3. Urine Albumin
10.2.2. Up-Regulated Proteins
10.2.2.1. Neutrophil Gelatinase-Associated Lipocalin
10.2.2.2. Kidney Injury Molecule-1
10.2.2.3. Interleukin-18
10.2.3. Others
10.3.Market Value Forecast By Diagnostic Technique , 2015–2026
10.3.1. Enzyme Linked Immunosorbent Assay (ELISA)
10.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)
10.3.3. Colorimetric Assay
10.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)
10.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)
10.4.Market Value Forecast By End User , 2015–2026
10.4.1. Diagnostic Labs
10.4.2. Outpatient Clinics
10.4.3. Research Centers
10.4.4. Hospitals
10.5.Market Value Forecast By Country , 2015–2026
10.5.1. Brazil
10.5.2. Mexico
10.5.3. Rest of Latin America
10.6.Market Attractiveness Analysis
10.6.1. By Biomarker Type
10.6.2. By Diagnostic Technique
10.6.3. By End User
10.6.4. By Country
10.7. Prominent Trends
10.8. Drivers and Restraints: Impact Analysis
11. Western Europe Renal Biomarker Market Analysis and Forecast
11.1.Introduction
11.1.1. Basis Point Share (BPS) Analysis By Country
11.1.2. Y-o-Y Growth Projections By Country
11.1.3. Key Regulations
11.2.Market Value Forecast By Biomarker Type , 2015–2026
11.2.1. Functional Biomarker
11.2.1.1. Serum Creatinine
11.2.1.2. Serum Cystatin C
11.2.1.3. Urine Albumin
11.2.2. Up-Regulated Proteins
11.2.2.1. Neutrophil Gelatinase-Associated Lipocalin
11.2.2.2. Kidney Injury Molecule-1
11.2.2.3. Interleukin-18
11.2.3. Others
11.3.Market Value Forecast By Diagnostic Technique , 2015–2026
11.3.1. Enzyme Linked Immunosorbent Assay (ELISA)
11.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)
11.3.3. Colorimetric Assay
11.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)
11.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)
11.4.Market Value Forecast By End User , 2015–2026
11.4.1. Diagnostic Labs
11.4.2. Outpatient Clinics
11.4.3. Research Centers
11.4.4. Hospitals
11.5.Market Value Forecast By Country , 2015–2026
11.5.1. Germany
11.5.2. France
11.5.3. Italy
11.5.4. Spain
11.5.5. The U.K.
11.5.6. BENELUX
11.5.7. Rest of Western Europe
11.6.Market Attractiveness Analysis
11.6.1. By Biomarker Type
11.6.2. By Diagnostic Technique
11.6.3. By End User
11.6.4. By Country
11.7. Prominent Trends
11.8. Drivers and Restraints: Impact Analysis
12. Eastern Europe Renal Biomarker Market Analysis and Forecast
12.1.Introduction
12.1.1. Basis Point Share (BPS) Analysis By Country
12.1.2. Y-o-Y Growth Projections By Country
12.1.3. Key Regulations
12.2.Market Value Forecast By Biomarker Type , 2015–2026
12.2.1. Functional Biomarker
12.2.1.1. Serum Creatinine
12.2.1.2. Serum Cystatin C
12.2.1.3. Urine Albumin
12.2.2. Up-Regulated Proteins
12.2.2.1. Neutrophil Gelatinase-Associated Lipocalin
12.2.2.2. Kidney Injury Molecule-1
12.2.2.3. Interleukin-18
12.2.3. Others
12.3.Market Value Forecast By Diagnostic Technique , 2015–2026
12.3.1. Enzyme Linked Immunosorbent Assay (ELISA)
12.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)
12.3.3. Colorimetric Assay
12.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)
12.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)
12.4.Market Value Forecast By End User , 2015–2026
12.4.1. Diagnostic Labs
12.4.2. Outpatient Clinics
12.4.3. Research Centers
12.4.4. Hospitals
12.5.Market Value Forecast By Country , 2015–2026
12.5.1. Russia
12.5.2. Poland
12.5.3. Rest of Eastern Europe
12.6.Market Attractiveness Analysis
12.6.1. By Biomarker Type
12.6.2. By Diagnostic Technique
12.6.3. By End User
12.6.4. By Country
12.7. Prominent Trends
12.8. Drivers and Restraints: Impact Analysis
13. Asia Pacific Excluding Japan (APEJ) Renal Biomarker Market Analysis and Forecast
13.1.Introduction
13.1.1. Basis Point Share (BPS) Analysis By Country
13.1.2. Y-o-Y Growth Projections By Country
13.1.3. Key Regulations
13.2.Market Value Forecast By Biomarker Type , 2015–2026
13.2.1. Functional Biomarker
13.2.1.1. Serum Creatinine
13.2.1.2. Serum Cystatin C
13.2.1.3. Urine Albumin
13.2.2. Up-Regulated Proteins
13.2.2.1. Neutrophil Gelatinase-Associated Lipocalin
13.2.2.2. Kidney Injury Molecule-1
13.2.2.3. Interleukin-18
13.2.3. Others
13.3.Market Value Forecast By Diagnostic Technique , 2015–2026
13.3.1. Enzyme Linked Immunosorbent Assay (ELISA)
13.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)
13.3.3. Colorimetric Assay
13.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)
13.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)
13.4.Market Value Forecast By End User , 2015–2026
13.4.1. Diagnostic Labs
13.4.2. Outpatient Clinics
13.4.3. Research Centers
13.4.4. Hospitals
13.5.Market Value Forecast By Country , 2015–2026
13.5.1. China
13.5.2. India
13.5.3. ASEAN
13.5.4. Australia and New Zealand
13.5.5. Rest of APEJ
13.6.Market Attractiveness Analysis
13.6.1. By Biomarker Type
13.6.2. By Diagnostic Technique
13.6.3. By End User
13.6.4. By Country
13.7. Prominent Trends
13.8. Drivers and Restraints: Impact Analysis
14. Japan Renal Biomarker Market Analysis and Forecast
14.1.Introduction
14.1.1. Basis Point Share (BPS) Analysis By Country
14.1.2. Y-o-Y Growth Projections By Country
14.1.3. Key Regulations
14.2.Market Value Forecast By Biomarker Type , 2015–2026
14.2.1. Functional Biomarker
14.2.1.1. Serum Creatinine
14.2.1.2. Serum Cystatin C
14.2.1.3. Urine Albumin
14.2.2. Up-Regulated Proteins
14.2.2.1. Neutrophil Gelatinase-Associated Lipocalin
14.2.2.2. Kidney Injury Molecule-1
14.2.2.3. Interleukin-18
14.2.3. Others
14.3.Market Value Forecast By Diagnostic Technique , 2015–2026
14.3.1. Enzyme Linked Immunosorbent Assay (ELISA)
14.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)
14.3.3. Colorimetric Assay
14.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)
14.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)
14.4.Market Value Forecast By End User , 2015–2026
14.4.1. Diagnostic Labs
14.4.2. Outpatient Clinics
14.4.3. Research Centers
14.4.4. Hospitals
14.5.Market Attractiveness Analysis
14.5.1. By Biomarker Type
14.5.2. By Diagnostic Technique
14.5.3. By End User
14.6. Prominent Trends
14.7. Drivers and Restraints: Impact Analysis
15. Middle East and Africa (MEA) Renal Biomarker Market Analysis and Forecast
15.1.Introduction
15.1.1. Basis Point Share (BPS) Analysis By Country
15.1.2. Y-o-Y Growth Projections By Country
15.1.3. Key Regulations
15.2.Market Value Forecast By Biomarker Type , 2015–2026
15.2.1. Functional Biomarker
15.2.1.1. Serum Creatinine
15.2.1.2. Serum Cystatin C
15.2.1.3. Urine Albumin
15.2.2. Up-Regulated Proteins
15.2.2.1. Neutrophil Gelatinase-Associated Lipocalin
15.2.2.2. Kidney Injury Molecule-1
15.2.2.3. Interleukin-18
15.2.3. Others
15.3.Market Value Forecast By Diagnostic Technique , 2015–2026
15.3.1. Enzyme Linked Immunosorbent Assay (ELISA)
15.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)
15.3.3. Colorimetric Assay
15.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)
15.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)
15.4.Market Value Forecast By End User , 2015–2026
15.4.1. Diagnostic Labs
15.4.2. Outpatient Clinics
15.4.3. Research Centers
15.4.4. Hospitals
15.5.Market Value Forecast By Country , 2015–2026
15.5.1. GCC
15.5.2. South Africa
15.5.3. Rest of MEA
15.6.Market Attractiveness Analysis
15.6.1. By Biomarker Type
15.6.2. By Diagnostic Technique
15.6.3. By End User
15.6.4. By Country
15.7. Prominent Trends
15.8. Drivers and Restraints: Impact Analysis
16. Competition Landscape
16.1.Competition Dashboard
16.2.Market Share Analysis By Company (2015)
16.3.Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
16.3.1. Beckman Coulter, Inc. (Danaher Corporation)
16.3.2. Thermo Fisher Scientific Inc.
16.3.3. Abbott Laboratories
16.3.4. BIOPORTO A/S
16.3.5. Astute Medical, Inc.
16.3.6. Randox Laboratories Ltd.
17. Assumptions and Acronyms Used
18. Research Methodology
Renal Biomarker Market Reports - List of Tables
Table 1: Global Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Biomarker Type, 2015–2026
Table 2: Global Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Diagnostic Technique, 2015–2026
Table 3: Global Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Table 4: Global Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Region, 2015–2026
Table 5: North America Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 6: North America Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Biomarker Type, 2015–2026
Table 7: North America Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Diagnostic Technique, 2015–2026
Table 8: North America Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026
Table 9: Latin America Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 10: Latin America Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Biomarker Type, 2015–2026
Table 11: Latin America Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Diagnostic Technique, 2015–2026
Table 12: Latin America Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026
Table 13: Western Europe Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 14: Western Europe Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Biomarker Type, 2015–2026
Table 15: Western Europe Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Diagnostic Technique, 2015–2026
Table 16: Western Europe Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026
Table 17: Eastern Europe Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 18: Eastern Europe Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Biomarker Type, 2015–2026
Table 19: Eastern Europe Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Diagnostic Technique, 2015–2026
Table 20: Eastern Europe Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026
Table 21: APEJ Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 22: APEJ Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Biomarker Type, 2015–2026
Table 23: APEJ Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Diagnostic Technique, 2015–2026
Table 24: APEJ Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026
Table 25: Japan Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Biomarker Type, 2015–2026
Table 26: Japan Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Diagnostic Technique, 2015–2026
Table 27: Japan Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026
Table 28: MEA Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 29: MEA Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Biomarker Type, 2015–2026
Table 30: MEA Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Diagnostic Technique, 2015–2026
Table 31: MEA Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026
Renal Biomarker Market Reports - List of Figures
Figure 1: Global Renal Biomarker Market Share Analysis (%) By Biomarker Type, 2016, 2021 & 2026
Figure 2: Global Renal Biomarker Market Y-o-Y Growth (%) By Biomarker Type, 2015–2026
Figure 3: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Functional Biomarker Type Segment, 2015 – 2026
Figure 4: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Up-Regulated Proteins Biomarker Type Segment, 2015 – 2026
Figure 5: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Other Biomarker Type Segment, 2015 – 2026
Figure 6: Global Renal Biomarker Market Attractiveness Analysis By End User, 2016–2026
Figure 7: Global Renal Biomarker Market Value Share Analysis (%) By Diagnostic Technique, 2016, 2021 & 2026
Figure 8: Global Renal Biomarker Market Y-o-Y Growth (%) By Diagnostic Technique, 2015–2026
Figure 9: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Enzyme Linked Immunosorbent Assay Diagnostic Technique Segment, 2015 – 2026
Figure 10: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Particle-Enhanced Turbidimetric Immunoassay Diagnostic Technique Segment, 2015 – 2026
Figure 11: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Colorimetric Assay Diagnostic Technique Segment, 2015 – 2026
Figure 12: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Chemiluminescent Enzyme Immunoassay Diagnostic Technique Segment, 2015 – 2026
Figure 13: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Liquid Chromatography-Mass Spectrometry Diagnostic Technique Segment, 2015 – 2026
Figure 14: Global Renal Biomarker Market Attractiveness Analysis By Diagnostic Technique, 2016–2026
Figure 15: Global Renal Biomarker Market Value Share Analysis (%) By End User, 2016, 2021 & 2026
Figure 16: Global Renal Biomarker Market Y-o-Y Growth (%) By End User, 2015–2026
Figure 17: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Hospitals End User Segment, 2015 – 2026
Figure 18: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Research Centers End User Segment, 2015 – 2026
Figure 19: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Outpatient Clinics End User Segment, 2015 – 2026
Figure 20: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Diagnostic Labs End User Segment, 2015 – 2026
Figure 21: Global Renal Biomarker Market Attractiveness Analysis By End User, 2016–2026
Figure 22: Global Renal Biomarker Market Share Analysis (%) By Region, 2016, 2021 & 2026
Figure 23: Global Renal Biomarker Market Y-o-Y Growth (%) By Region, 2015–2026
Figure 24: North America Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 25: Latin America Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 26: Western Europe Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 27: Eastern Europe Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 28: APEJ Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 29: Japan Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 30: MEA Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 31: Global Renal Biomarker Market Attractiveness Analysis By Region, 2016–2026
Figure 32: North America Renal Biomarker Market Share Analysis (%) By Country, 2016, 2021 & 2026
Figure 33: North America Renal Biomarker Market Y-o-Y Growth (%) By Country, 2015–2026
Figure 34: U.S. Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 35: Canada Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 36: North America Renal Biomarker Market Attractiveness Analysis By Country, 2016 – 2026
Figure 37: North America Renal Biomarker Market Attractiveness Analysis By Biomarker Type, 2016 – 2026
Figure 38: North America Renal Biomarker Market Attractiveness Analysis By Diagnostic Technique, 2016 – 2026
Figure 39: North America Renal Biomarker Market Attractiveness Analysis By End User, 2016 – 2026
Figure 40: Latin America Renal Biomarker Market Share Analysis (%) By Country, 2016, 2021 & 2026
Figure 41: Latin America Renal Biomarker Market Y-o-Y Growth (%) By Country, 2015–2026
Figure 42: Brazil Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 43: Mexico Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 44: Rest of Latin America Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 45: Latin America Renal Biomarker Market Attractiveness Analysis By Country, 2016 – 2026
Figure 46: Latin America Renal Biomarker Market Attractiveness Analysis By Biomarker Type, 2016 – 2026
Figure 47: Latin America Renal Biomarker Market Attractiveness Analysis By Diagnostic Technique, 2016 – 2026
Figure 48: Latin America Renal Biomarker Market Attractiveness Analysis By End User, 2016 – 2026
Figure 49: Western Europe Renal Biomarker Market Share Analysis (%) By Country, 2016, 2021 & 2026
Figure 50: Western Europe Renal Biomarker Market Y-o-Y Growth (%) By Country, 2015–2026
Figure 51: Germany Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 52: France Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 53: Italy Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 54: Spain Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 55: The U.K. Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 56: BENELUX Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 57: Rest of Western Europe Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 58: Western Europe Renal Biomarker Market Attractiveness Analysis By Country, 2016 – 2026
Figure 59: Western Europe Renal Biomarker Market Attractiveness Analysis By Biomarker Type, 2016 – 2026
Figure 60: Western Europe Renal Biomarker Market Attractiveness Analysis By Diagnostic Technique, 2016 – 2026
Figure 61: Western Europe Renal Biomarker Market Attractiveness Analysis By End User, 2016 – 2026
Figure 62: Eastern Europe Renal Biomarker Market Share Analysis (%) By Country, 2016, 2021 & 2026
Figure 63: Eastern Europe Renal Biomarker Market Y-o-Y Growth (%) By Country, 2015–2026
Figure 64: Russia Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 65: Poland Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 66: Rest of Eastern Europe Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 67: Eastern Europe Renal Biomarker Market Attractiveness Analysis By Country, 2016 – 2026
Figure 68: Eastern Europe Renal Biomarker Market Attractiveness Analysis By Biomarker Type, 2016 – 2026
Figure 69: Eastern Europe Renal Biomarker Market Attractiveness Analysis By Diagnostic Technique, 2016 – 2026
Figure 70: Eastern Europe Renal Biomarker Market Attractiveness Analysis By End User, 2016 – 2026
Figure 71: APEJ Renal Biomarker Market Share Analysis (%) By Country, 2016, 2021 & 2026
Figure 72: APEJ Renal Biomarker Market Y-o-Y Growth (%) By Country, 2015–2026
Figure 73: China Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 74: India Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 75: ASEAN Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 76: Australia and New Zealand Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 77: Rest of APEJ Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 78: APEJ Renal Biomarker Market Attractiveness Analysis By Country, 2016 – 2026
Figure 79: APEJ Renal Biomarker Market Attractiveness Analysis By Biomarker Type, 2016 – 2026
Figure 80: APEJ Renal Biomarker Market Attractiveness Analysis By Diagnostic Technique, 2016 – 2026
Figure 81: APEJ Renal Biomarker Market Attractiveness Analysis By End User, 2016 – 2026
Figure 82: Japan Renal Biomarker Market Attractiveness Analysis By Biomarker Type, 2016 – 2026
Figure 83: Japan Renal Biomarker Market Attractiveness Analysis By Diagnostic Technique, 2016 – 2026
Figure 84: Japan Renal Biomarker Market Attractiveness Analysis By End User, 2016 – 2026
Figure 85: MEA Renal Biomarker Market Share Analysis (%) By Country, 2016, 2021 & 2026
Figure 86: MEA Renal Biomarker Market Y-o-Y Growth (%) By Country, 2015–2026
Figure 87: GCC Countries Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 88: South Africa Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 89: Rest of MEA Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 90: MEA Renal Biomarker Market Attractiveness Analysis By Country, 2016 – 2026
Figure 91: MEA Renal Biomarker Market Attractiveness Analysis By Biomarker Type, 2016 – 2026
Figure 92: MEA Renal Biomarker Market Attractiveness Analysis By Diagnostic Technique, 2016 – 2026
Figure 93: MEA Renal Biomarker Market Attractiveness Analysis By End User, 2016 – 2026